Integrated HIV surveillance finds recent adult hepatitis B virus (HBV) transmission and intermediate HBV prevalence among military in uncharacterized Caribbean country

Siobhan M. O’Connor¹, Tonya Mixson-Hayden¹, Lilia Ganova-Raeva¹, Djeneba Audrey Djibo², Matthew Brown³, Guo-Liang Xia¹, Saleem Kamili¹, Marni Jacobs³, Maxia Dong⁴, Anne G. Thomas², Marc Bulterys²

¹ Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, United States Centers for Disease Control and Prevention, Atlanta, GA, United States of America, ² Department of Defense HIV/AIDS Prevention Program, United States Naval Health Research Center, San Diego, CA, United States of America, ³ Division of Global HIV and Tuberculosis, Center for Global Health, United States Centers for Disease Control and Prevention, Atlanta, GA, United States of America, ⁴ Division of Global HIV and Tuberculosis, United States Centers for Disease Control and Prevention, CDC Guyana, Georgetown, Guyana

Abstract

Background
Guyana expanded its HIV response in 2005 but the epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections has not been characterized.

Methods
The 2011 Seroprevalence and Behavioral Epidemiology Risk Survey for HIV and STIs collected biologic specimens with demographic and behavioral data from a representative sample of Guyana military personnel. Diagnostics included commercial serum: HIV antibody; total antibody to hepatitis B core (anti-HBc); IgM anti-HBc; hepatitis B surface antigen (HBsAg); anti-HBs; antibody to HCV with confirmatory testing; and HBV DNA sequencing with S gene fragment phylogenetic analysis. Chi-square, p-values and prevalence ratios determined statistical significance.
Results

Among 480 participants providing serologic specimens, 176 (36.7%) tested anti-HBc-positive. Overall, 19 (4.0%) participants tested HBsAg-positive; 17 (89.5%) of the HBsAg-positive participants also had detectable anti-HBc, including 1 (5.3%) IgM anti-HBc-positive male. Four (6.8%) females with available HBV testing were HBsAg-positive, all aged 23–29 years. Sixteen (16, 84.2%) HBsAg-positive participants had sufficient specimen for DNA testing. All 16 had detectable HBV DNA, 4 with viral load >2x10^4 IU/ml. Sequencing found: 12 genotype (gt) A1 with 99.9% genetic identity between 1 IgM anti-HBc-positive and 1 anti-HBc-negative; 2 gtD1; and 2 with insufficient specimen. No statistically significant associations between risk factors and HBV infection were identified.

Conclusions

Integrated HIV surveillance identified likely recent adult HBV transmission, current HBV infection among females of reproductive age, moderate HBV infection prevalence (all gtA1 and D1), no HCV infections and low HIV frequency among Guyana military personnel. Integrated HIV surveillance helped characterize HBV and HCV epidemiology, including probable recent transmission, prompting targeted responses to control ongoing HBV transmission and examination of hepatitis B vaccine policies.

Introduction

The Cooperative Republic of Guyana (Guyana) in the Caribbean region (northeast South America), was heavily impacted by the human immunodeficiency virus (HIV) epidemic [1–2]. In 2003, an estimated 2.5% of the general population, including pregnant women, were infected with HIV [3]; and by 2006, HIV/AIDS was the leading cause of death among persons aged 15–44 years (who comprised >50% of the population) [4]. Following expansion of HIV prevention and treatment efforts, 2011 Guyana general population-based surveillance estimated a decrease in HIV prevalence to 1.1% among persons aged 15–49 years [4–6]. The 2008–2009 national behavioral survey included military personnel and identified gaps in HIV prevention and knowledge among military but did not include biologic testing for infections [4]. In general, military populations are at increased risk for sexually transmitted infections (STIs) [7–9].

The epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections in Guyana is not well characterized [10–11]. However, an estimated 2–4% of persons in Latin America and the Caribbean (LAC) are infected with HBV. Rates range from <2% to >8%, even 10–30% among indigenous peoples, and genotypes (gt) associated with severe disease are reported [10–17]. Furthermore, an estimated 7–9 million persons in LAC live with chronic HCV infection. Moderate HCV infection prevalence is reported in countries bordering Guyana but published Caribbean-specific HCV infection epidemiology and gt data are limited [10–11, 18–19].

Understanding the epidemiology of HBV and HCV infections in Guyana is important. Globally, HBV- and HCV-related deaths have been increasing over time. HBV- and HCV-related chronic liver disease and hepatocellular cancer accounted for an estimated 720,000 and 470,000 deaths in 2015 [10, 20]. Furthermore, HBV and HCV are opportunistic co-infections with HIV that may negatively impact HIV outcomes [21–25] so a good understanding of HBV...
and HCV treatment needs within HIV programs is essential. This report describes the first effort to define the epidemiology of HBV and HCV infections and co-infections with HIV in the Guyana general population or military forces, with associated risk factors, by integrating HBV and HCV testing into HIV surveillance among military personnel. The data can inform prevention and control policy and programs.

Methods

Study design and population

The Seroprevalence and Behavioral Epidemiology Risk Survey (SABERS) implements cross-sectional behavioral risk questionnaires paired with biologic specimen collection for HIV and STI (not previously including viral hepatitis) testing from representative members of military forces in lower resourced nations [26]. The 2011 Guyana Defence Force (GDF) SABERS incorporated testing for acute and chronic HBV infection plus evidence of HCV exposure and infection. Briefly, the GDF invited all active military personnel aged ≥18 years (yr) to participate. Using a stratified proportional sampling scheme of all military personnel based on rank distribution at each base, the survey target sample size of 500 was calculated to represent 20% of the total active military population and fulfill the primary SABERS objective, to determine HIV prevalence in the combined military forces. Sampling assumed a general population HIV prevalence rate of 2.4% (95% confidence interval [CI] 0.8%–4.1%) [27]. Female personnel were separately recruited to compose 10% of the sample, equivalent to the proportion of females in the Forces. Of note, females are not stationed in remote areas.

This study was approved by the institutional review boards of the Guyana Ministry of Health and Naval Health Research Center (NHRC) in San Diego, California.

Collection of demographics, behavioral history and biologic specimens

All participants provided their written free and informed consent to participate and give biologic specimens. Trained survey staff provided pre-survey counseling and proctored participants, who self-administered the written behavioral risk survey. To protect anonymity, each participant was assigned a randomly generated numerical code not linked to names. The questionnaire adapted existing SABERS and Guyana Demographic and Health Survey forms to collect demographics, military service history and self-reported HIV risk behaviors [26–27]. Questions about risk behaviors during the preceding 12 months included queries about alcohol use, illicit drug use and injection drug use (IDU), sexual preference, and sexual practices and experiences. Trained phlebotomists collected venous blood for HIV, HBV, HCV and syphilis testing and participants provided urine for chlamydia and gonorrhea analysis. The Force Medical Officer provided test results and post-test counseling to participants with the corresponding numerical code and referred infected participants to standard care in the civilian sector. This report outlines only the HBV, HCV and HIV test results and risk factors associated with those infections.

Laboratory testing

HIV testing followed the existing Guyana national testing guidelines [28]. The Guyana National Public Health Reference Laboratory performed parallel, dual rapid testing for antibody to HIV (Inverness Medical Determine HIV-1/2 Ag/Ab Combo [Alere], Inverness Medical Innovations, Inc., Waltham, MA; and Trinity Biotech Unigold Recombigen, Trinity Biotech PLC, Bray, Ireland) with a tie-breaker test (Chembio Stat-Pak, ChemBio Diagnostic Systems, Inc., Medford, NY) for discordant results. Venous blood was processed and serum
frozen. Stored serum was shipped to the CDC Division of Viral Hepatitis for hepatitis B surface antigen (HBsAg), total antibody to hepatitis B core antigen (total anti-HBc), antibody to hepatitis B surface antigen (anti-HBs), immunoglobulin M (IgM) anti-HBc as indicated, and antibody to HCV (anti-HCV) testing on an automated platform (Ortho VITROS ECi, Ortho Clinical Diagnostics, Inc., Raritan, NJ). All available participant sera underwent testing for total anti-HBc, HBsAg and anti-HBs. Those with detectable HBsAg (HBsAg-positive) were further tested for IgM anti-HBc and underwent polymerase chain reaction testing (COBAS® AmpliPrep®/COBAS® TaqMan® HBV v2.0, Roche Diagnostics, Indianapolis, IN) with quantification of HBV viral load (HBV VL). Specimens reactive for anti-HCV (anti-HCV-positive) underwent still available recombinant immunoblot assay (RIBA, CHIRON® RIBA® HCV 3.0 SIA, Novartis Vaccines and Diagnostics, Inc., Emeryville, CA); and RIBA-positive specimens were further tested for HCV RNA (COBAS® TaqMan® HCV Test v2, Roche Diagnostics, Indianapolis, IN).

**Phylogenetic analysis**

Specimens with detectable HBV DNA underwent full genome sequencing with phylogenetic analysis of an S gene fragment and characterization of genetic identity [29–31]. Nucleotide sequences were aligned using the Geneious (Version 7.1.5, Biomatters Limited, Auckland, New Zealand) Align/Assemble program. HBV gt was classified based on the S-gene sequence and confirmed with whole-genome sequences by comparing each sequence with published reference sequences from GenBank. Initial neighbor-joining trees were built using the Kimura two-parameter model of nucleotide substitution [31]. Phylogenetic trees were constructed using the maximum likelihood algorithm implemented in DNAML (PHYLIP package, v.3.6).

**Classification of infection**

Two concordant positive HIV screening tests or a positive HIV tie-breaker test signified HIV infection (HIV-positive). HBsAg-positive results indicated active HBV infection. Detection of IgM anti-HBc (IgM anti-HBc-positive) signified acute, recent HBV infection within the 6 months preceding venipuncture. Detection of anti-HBs (anti-HBs-positive) in the absence of HBsAg defined either HBV immune status after resolved infection (anti-HBs-positive) or previous hepatitis B immunization (anti-HBs-positive). Detection of isolated total anti-HBc in the absence of other detectable HBV markers was classified as indeterminate infection. Confirmation of anti-HCV-positive status by RIBA indicated HCV infection at some time but only detection of HCV RNA (HCV RNA-positive results) signified current HCV infection.

**Statistical analysis**

Trained staff double entered information into Epi Info™ 7 (CDC, Atlanta, GA). Denominators for HBV and HCV infection frequencies equaled the number of participants having sufficient specimen to perform both HBsAg and anti-HBc testing, or anti-HCV testing, respectively, and frequency comparisons were restricted to those participants; behavioral analyses reflected participants having both HBV results and a completed questionnaire for that risk factor. Statistical analyses were performed using SAS Version 9.3 (SAS Institute, Cary, NC) and Epi Info™ 7. Chi-square test for independence, p-values generated using the Fisher exact test or two sample z-test comparison of proportions and prevalence ratios (PR) with 95% confidence intervals (CI) derived using maximum likelihood estimates determined statistical significance.
Results

HBV and HCV testing

Among 502 total participants, 480 (95.6%) had sufficient serum for both HBsAg and total anti-HBc testing; the HBV frequency denominator is defined as the number of participants with results for both HBsAg and anti-HBc testing. Of the 480, 176 (36.7%) tested total anti-HBc-positive. While 19 (4.0%) tested HBsAg-positive, only 17 (89.5%) HBsAg-positives had detectable anti-HBc, including 1 (5.3%) IgM anti-HBc-positive male (Fig 1). Frequency of HBsAg detection by sex was not statistically different (males 3.7% vs. females 6.8%, p = 0.20). Of the 19 HBsAg-positive participants, 17 (89.5%) were aged 20-34yr (Table 1), statistically similar to the survey age distribution (S1 Table). All 4 HBsAg-positive females were aged 20-29yr; although younger than male counterparts, the difference was not statistically significant.

Among the 19 HBsAg-positive participants, 15 had sufficient specimen for IgM anti-HBc testing, with only 1 male having detectable IgM anti-HBc (3 males and 1 female had insufficient specimen). Overall, 103 (21.4%) of participants with HBV test results had undetectable anti-HBs. This included 95 (20.6%) HBsAg-negative/anti-HBc-negative participants, while 177 (38.4%) of all HBsAg-negative participants demonstrated anti-HBs levels <10 mIU/mL.

Sixteen (16) HBsAg-positive participants had sufficient specimen for DNA testing; all 16 were HBV DNA-positive. VLs varied between 3.10 x 10^1 IU/ml and 1.33 x 10^9 IU/ml; and 4 (25.0%) had HBV VL >2.00 x 10^4 IU/ml, including 1 female with VL 6.98 x 10^8. Of the 16, 2 (12.5%) had anti-HBs titers >10mIU/ml (12.5 and 86.2mIU/ML), with HBV VL 1.33 x 10^9 and 4.85 x 10^2, respectively.

Testing detected no current HCV infections. Four (0.8%) individuals initially tested anti-HCV-positive but HCV infection could not be confirmed: 2 RIBA-negative; and 2 RIBA-indeterminate with no detectable HCV RNA.

HBV phylogenetic analysis

Genotyping by S gene sequencing of 14 HBV DNA-positive participants with sufficient specimen identified 12 (85.7%) gtA1 cases, in which 1 case had 2 gtA1 variants, and 2 (14.3%) gtD1

![Fig 1. Hepatitis B virus (HBV) testing with results, 2011 Guyana Defense Force Seroprevalence and Behavioral Epidemiology Risk Survey for HIV and sexually transmitted infections. Abbreviations: Anti-HBc, antibody to hepatitis B core antigen; Anti-HBs, antibody to hepatitis B surface antigen; DNA, deoxyribonucleic acid; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IgM, immunoglobulin M; mIU/ml, milli-international units per milliliter; ND, not detected; QNS, quantity not sufficient for testing.](https://doi.org/10.1371/journal.pone.0222835.g001)
cases. The 2 gtD1 infections were genetically identical in the S gene region (Fig 2), as were 4 gtA1 cases. Complete genome sequencing was successful for 6 of the genotyped cases (Table 1). Two males and 1 female with gtA1 infections demonstrated \( \geq 98.6\% \) sequence identity at the complete genome level as well as the S gene.

\[ 0.005 = \text{sequence distance unit (number of changes per 100 nucleotides); sequence names starting with GDF are HBV DNA-positive cases and all other notations represent reference sequences with corresponding GenBank number and genotype.} \]

**HIV testing**

Only 1 participant tested HIV-positive, without evidence of HBV or HCV co-infection.

**Population characteristics, behavioral survey results and correlation with laboratory results**

Combined, 469 participants (410 males and 59 females) with HBV testing submitted questionnaires, including all HBsAg-positive participants. The denominators to calculate risk factor frequency equaled the number of participants who responded to each specific risk factor.
question. The age distribution of participants completing questionnaires was as follows: 9.7% (18-19yr); 45.3% (20-24yr); 23.4% (25-29yr); 14.9% (30-34yr); 4.7% (35-39yr); and 3.0% (>40yr). Seventeen (89.5%) HBsAg-positive participants self-identified as Afro-Guyanese and 2 (10.5%) as mixed race, statistically similar to the survey population composition (prevalence ratio [PR] 1.4, 95% CI, 0.5–4.2) (Table 2). Most (70.8%) were born in populated coastal areas and only 3.5% in the non-coastal and remote hinterland (densely forested, jungle) regions; HBsAg-positive frequency did not differ by region of birth (PR 3.2, 95% CI, 0.4–24.0). Only 1 HBsAg-positive participant reported IDU compared with 5 HBsAg-negative participants (PR 4.4, 95% CI, 0.7–27.8).

Among 158 participants reporting non-regular sexual partners during the preceding 12 months, the prevalence ratio did not suggest an association between unprotected sex and HBV infection (Table 2). However, only 39% reported knowing the HIV status of their non-regular partner. Similarly, of 87 participants reporting one or more transactional partners, only 59% reported using a condom at last sex and 48% at every encounter with those partners; just 41% of this group reported knowing the HIV status of the transactional partner. Across all respondents, HBV infection was not associated with number of sexual partners or unprotected sex (Table 2). Only 1 participant reported same sex partners. Twenty-two percent of males had been circumcised (at median age 10yr) and another 36% reported willingness to get circumcised. Notably, 7.9% of respondents believed that HIV could be transmitted by sharing a meal with an infected person and 12.0% were not sure if this was possible; 4.3% thought HIV could be transmitted by mosquito bites, while another 17.5% did not know if mosquito transmission was possible.

**Discussion**

Integrating HBV and HCV testing into the 2011 GDF SABERS HIV surveillance provided the first indication of intermediate HBV and low HCV infection prevalence in any segment of the
Guyana population. It also identified recent, acute adult HBV infection with likely HBV transmission among military personnel; the >99.1% genetic identity between 2 participant infections, including 1 IgM anti-HBc-positive male, is consistent with both a common source of infection and recent infection. We cannot, however, differentiate between direct person-to-person transmission and transmission through a common intermediary such as a shared infected sexual partner, shared personal hygiene implements or a close household contact. Living conditions in the remote military camps were rudimentary and lapses in hygiene, such as sharing of razors, toothbrushes or other personal implements, cannot be ruled out; suspected adult HBV and HCV transmission through shared razors at community barbers has been reported elsewhere [32, 33]. Although IDU behaviors might be under-reported, Guyana health officials indicate that IDU is uncommon in Guyana. No recent local viral hepatitis transmission through transfusions, lapses in infection control, unsafe injections or cultural practices (breaching the skin) that might explain the findings have been recognized.

The >98.1% genetic identity among >30% of the remaining gtA1 HBV infections suggests closely related sources. Those infections were not recent but this survey cannot determine whether HBV infection occurred during early childhood or later yet >6 months before the survey. The anonymity of SABERS methodology prevents determining whether participants were related by parentage or co-habitation (potential perinatal or household transmission).

Table 2. Frequency of self-reported demographic and behavioral risk factors by hepatitis B virus infection status among military forces, 2011 Guyana Defence Force Seroprevalence and Behavioral Epidemiology Risk Survey for HIV and sexually transmitted infections.

| Risk factor                                        | Males and females combined |
|----------------------------------------------------|---------------------------|
| Risk factor frequency by HBsAg status              | n (%) of HBsAg-positive or-negative | Prevalence ratio (95% CI) |
| Race/ethnicity                                     | Number of responses* n    | HBsAg-positive | HBsAg-negative |
| Afro-Guyanese                                      | 439                       | 15 (78.9)     | 304 (72.4)     | 1.4 (0.5–4.2) |
| Other                                              |                           | 4 (21.1)      | 116 (27.6)     | 1.0          |
| Birth region                                       | 451                       |               |                |
| Coastalb                                           |                           | 18 (94.7)     | 364 (84.3)     | 3.2 (0.4–24.0)|
| Non-coastal and remote hinterlandsc                |                           | 1 (5.3)       | 68 (15.7)      | 1.0          |
| Ever stationed remotely                            | 466                       | 7 (36.8)      | 189 (42.3)     | 0.9 (0.5–1.5)|
| Illicit drug use                                   | 418                       | 1 (6.3)       | 40 (10.0)      | 0.6 (0.1–4.5)|
| Injection drug use                                 | 466                       | 1 (5.3)       | 5 (1.1)        | 4.4 (0.7–27.8)|
| Lifetime number of sexual partners                 | 425                       | 6.8 (4.1)     | 8.2 (9.2)      |              |
| ≤4                                                  |                           | 8 (47.1)      | 115 (28.2)     | 1.3 (0.4–4.8)|
| 5–10                                               |                           | 6 (35.3)      | 235 (57.6)     | 0.5 (0.1–2.0)|
| >11+                                               |                           | 3 (17.6)      | 58 (14.2)      | 1.0          |
| Inconsistent condom use with regular sexual partnerd| 402                       | 15 (79.0)     | 289 (75.5)     | 1.2 (0.4–3.6)|
| Inconsistent condom use with non-regular sexual partnere| 158                       | 5 (62.5)      | 96 (64.0)      | 0.9 (0.2–3.8)|

*Analysis restricted to number of participants who responded to each question.

Coastal regions by number and name: 2 (Pomeroon-Supenaam), 3 (Essequibo Islands–West Demerara), 4 (Demerara-Mahaica), 5 (Mahaica-Berbice), 6 (East Berbice-Corentyne).

Non-coastal and remote hinterland regions by number and name: 1 (Barima-Waini), 7 (Cuyuni-Mazaruni), 8 (Potaro-Siparuni), 9 (Upper Takatu-Upper Essequibo), 10 (Upper Demerara-Berbice).

Analysis further restricted to participants reporting regular sexual partners during the preceding 12 months.

Analysis further restricted to participants reporting non-regular sexual partners during the preceding 12 months.

Abbreviations: CI, confidence interval; HBsAg, hepatitis B surface antigen

https://doi.org/10.1371/journal.pone.0222835.t002
Nevertheless, the findings indicate that recent transmission with acute infection(s) occurred and could continue.

Two other findings have important implications for hepatitis B prevention and care programs and policy. Fully 6.8% of participating females—all of reproductive age—evidenced chronic HBV infection, 1 with VL $>6.9 \times 10^7$ IU/ml, representing high risk for mother-to-child HBV transmission if pregnancy occurred; but the Guyana immunization schedule does not include routine (universal) hepatitis B vaccine birth dose or hepatitis B immune globulin for optimal prevention of mother-to-child HBV transmission [34–35]. Additionally, 20.6% of participants demonstrated no immunity to HBV infection and another 38.4% were possibly not protected (low anti-HBs titers). They represent a substantial proportion of the military and an age cohort not captured by the high-performing Guyana routine childhood immunization program, which has included the routine hepatitis B vaccine series since 2001 [36]. Therefore this cohort represents a reservoir of susceptibles at risk for future HBV infection and ongoing transmission. Additionally, World Health Organization guidelines recommend that all HBsAg-positive individuals should be assessed for cirrhosis and counseled regarding risk for transmission to others [37].

Detection of only 1 HIV-infected individual suggests that HIV education and prevention efforts have had an impact. However, participant questionnaire responses indicate substantial lapses in safe sexual behaviors and misconceptions about HIV transmission among the military personnel. Paired with rising STI rates among Guyanese adults and youths when the survey was conducted [3, 4], the findings indicate that further HIV and STI education was still needed. Progress in the Guyana response to its HIV/AIDS epidemic was reported elsewhere by the Republic of Guyana [38].

The survey findings are subject to several limitations. The results and conclusions of a survey among military personnel might not be generalized to the general population. Furthermore, the small sample size and voluntary nature of participation could have introduced bias into sampling, underestimating HIV, HBV and HCV infection prevalence. Individuals already aware of their HIV status, particularly those who are HIV-infected, may have chosen not to participate because they did not perceive personal value in participating. Although the GDF has a liberal policy of HIV tolerance, and HIV infection status does not impact service eligibility or advancement, fear of public knowledge of personal HIV status might still have deterred the participation of HIV-infected staff. Lastly, underreporting of IDU and sexual risk behaviors might have occurred, and the survey did not include mechanisms to verify the responses.

In conclusion, the addition of HBV and HCV testing to HIV surveillance in the 2011 GDF SABERS provided actionable public health findings with implications for viral hepatitis prevention and care. The addition of IgM and total anti-HBc, anti-HBs, HBV DNA and HBV phylogenetic analysis to HBsAg testing identified likely ongoing recent HBV transmission between adult military personnel, active HBV infection among women of reproductive age and a high frequency of HBV susceptibility in the survey population. Although not necessarily representative of the general population of Guyana, the findings still provide important insight into HBV and HCV infection prevalence, risk and, importantly, the potential for preventable mother-to-child HBV transmission in this previously uncharacterized region of LAC. In particular, high HBV infection rates and HBV VL in females of reproductive age highlight the need to address national immunization policies and antenatal care practice, particularly the addition of universal hepatitis B vaccine birth dose delivery, HBsAg testing of pregnant females and hepatitis B vaccination of susceptible young adults. It also highlights the need for hepatitis B vaccination among military personnel, particularly in the setting of known recent transmission, and inclusion of females of reproductive age [34–35]. In response to the findings, the GDF began implementing measures to interrupt and prevent further HBV transmission.
Supporting information

S1 Table. Age distribution by hepatitis B virus infection status among military forces, 2011 Guyana Defence Force Seroprevalence and Behavioral Epidemiology Risk Survey for HIV and sexually transmitted infections. (DOCX)

Acknowledgments

We gratefully acknowledge the implementation contributions of Joyce White-Chin, PhD, National Public Health Laboratory, Ministry of Health, Guyana; Beverly Gomes-Lovell, BSc, Department of Defense HIV/AIDS Prevention Program, Guyana; Col. Frederick Deane, MD, Lt. Col. Walter Morris and other members of the Guyana Defence Force; the Guyana Ministry of Health, including Shanti Singh, MD, MPH; and Colin Roach, PhD, formerly of the Guyana NPHL. We also gratefully acknowledge the technical assistance, training and capacity building for HBV, CT, GC and syphilis of colleagues Alexandra Tejada-Strop, BS, John R. Papp, PhD, Chen Y. Chen, PhD and Carol Farshy, BS, MPH.

Author Contributions

Conceptualization: Siobhan M. O’Connor, Matthew Brown, Marni Jacobs, Braden Hale.

Data curation: Siobhan M. O’Connor, Djeneba Audrey Djibo, Marni Jacobs.

Formal analysis: Siobhan M. O’Connor, Tonya Mixson-Hayden, Lilia Ganova-Raeva, Djeneba Audrey Djibo, Guo-Liang Xia, Saleem Kamili, Marni Jacobs, Anne G. Thomas, Marc Bulterys.

Funding acquisition: Braden Hale.

Investigation: Siobhan M. O’Connor, Djeneba Audrey Djibo, Matthew Brown, Marni Jacobs, Maxia Dong.

Methodology: Siobhan M. O’Connor, Tonya Mixson-Hayden, Lilia Ganova-Raeva, Djeneba Audrey Djibo, Matthew Brown, Guo-Liang Xia, Saleem Kamili, Marni Jacobs, Braden Hale.

Supervision: Matthew Brown, Marni Jacobs, Marc Bulterys, Braden Hale.

Validation: Tonya Mixson-Hayden, Lilia Ganova-Raeva, Djeneba Audrey Djibo, Guo-Liang Xia.

Writing – original draft: Siobhan M. O’Connor, Tonya Mixson-Hayden, Lilia Ganova-Raeva, Djeneba Audrey Djibo, Matthew Brown, Guo-Liang Xia, Saleem Kamili, Marni Jacobs, Maxia Dong, Anne G. Thomas, Marc Bulterys, Braden Hale.

Writing – review & editing: Siobhan M. O’Connor, Tonya Mixson-Hayden, Lilia Ganova-Raeva, Djeneba Audrey Djibo, Matthew Brown, Saleem Kamili, Marni Jacobs, Maxia Dong, Anne G. Thomas, Marc Bulterys, Braden Hale.

References

1. UNAIDS. WHO Epidemiological Fact Sheet– 2004 Update. Available at: www.data.unaids.org/publications/Fact-Sheets01/guayana_en.pdf. Accessed 26 September 2013.
2. UNAIDS. Global Report. UNAIDS report on the global HIV epidemic 2013. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf. Accessed 10 January 2014.
3. Ministry of Health Guyana. Behavioral Surveillance Survey, Executive Summary, Round I: 2003/2004. Available at: http://dspace.africaportal.org/jspui/bitstream/123456789/8297/1/Behavioural%20Surveillance%20Survey%20Guyana%202004.pdf?1. Accessed 01 April 2014.

4. Guyana Ministry of Health, National AIDS Programme. 2009. Guyana Behavioral Surveillance Surveys: 2008/2009 Report, including a Comparative Analysis with 2003/2004 BSS Results.

5. Government of Guyana-United Nations General Assembly Special Session on HIV/AIDS Progress Report, 2008–2009. Available at: http://www.unaids.org/sites/default/files/en/dataanalysis/knowyoursresponse/countryprogressreports/2010countries/guyana_2010_country_progress_report_en.pdf. Accessed 01 April 2014.

6. Ministry of Health, Guyana. Guyana National HIV/AIDS Strategy 2007–2011. Available at: http://www.pancap.org/docs/NSP/Guyana_NSP.pdf. Accessed 02 March 2014.

7. Lloyd J, Papworth E, Grant L, Beyrer C, Baral S. Systematic review and meta-analysis of HIV prevalence among men in militaries in low income and middle income countries. Sex Transm Infect 2014 Aug; 90(5):382–387. https://doi.org/10.1136/sextrans-2013-051463 PMID: 24711546

8. Stahlman S, Javanbakht M, Cochran S, Hamilton AB, Shoptaw S, Gorbach PM. Self-reported sexually transmitted infections and sexual risk behaviors in the U.S. Military: how sex influences risk. Sex Transm Dis 2014 Jun; 41(6):359–64. https://doi.org/10.1097/OLQ.0000000000000133 PMID: 24825331

9. Anastario M, Manzanero R, Blanco R, Reyes E, Jaramillo R, Black L, et al. HIV infection, sexual risk behaviour and condom use in the Belize defense force. Int J STD AIDS 2011 Feb; 22(2):73–9. https://doi.org/10.1258/ija.2010.010274 PMID: 21427427

10. Global Hepatitis Report 2017. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

11. Schweitzer A, Horn J, Nikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet 2015 Oct 17; 386(10003):1546–55. https://doi.org/10.1016/S0140-6736(15)61412-X PMID: 26231459

12. Alvarado-Mora MV, Pinho JR. Epidemiological update of hepatitis B, C and delta in Latin America. Anti- vir Ther 2013; 18(3 part B):429–33.

13. Brichler S, Lagathu G, Chekaraou MA, Le Gal F, Edouard A, Dény P, et al. African, Amerindian and European hepatitis B virus strains circulate on the Caribbean Island of Martinique. J Gen Virol 2013 Oct; 94(10 Pt 1):2318–29. https://doi.org/10.1099/vir.0.055459-0 PMID: 23884366

14. Couto CA, Levy C, Morris CJ, Hill M, de Medina M, Sanborn MR, et al. High frequency of genotype D and spontaneous hepatitis B virus genomic mutations among Haitians in a multiethnic North American population. J Clin Gastroenterol 2013 Jan; 47(1):83–8. https://doi.org/10.1097/MCG.0b013e318268003b PMID: 23059410

15. Crispim MAE, Fraiji NA, Campello SC, Schriefer NA, Stefani MM, Kiesslich D. Molecular epidemiology of hepatitis B and hepatitis delta viruses circulating in the Western Amazon region, North Brazil. BMC Infectious Diseases 2014 Feb 21; 14:94. Available at: http://www.biomedcentral.com/1471-2334/14/94. Accessed 27 August 2015. https://doi.org/10.1186/1471-2334-14-94 PMID: 24555665

16. Barros LM, Gomes-Gouveia MS, Kramvis A, Mendes-Corrêa MC, dos Santos A, Souza LA, et al. High prevalence of hepatitis B virus subgenotypes A1 and D4 in Maranhão state, Northeast Brazil. Infect Genet Evol 2014 Jun; 24:68–75. https://doi.org/10.1016/j.meegid.2014.03.007 PMID: 24642137

17. Alvarado-Mora MV, Pinho JR. Distribution of HBV genotypes in Latin America. Antivir Ther 2013; 18(3 Pt B):459–65.

18. Hanafiah KM, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013 Apr; 57(4):1333–42. https://doi.org/10.1002/hep.26141 PMID: 23172780

19. Alonso M, Gutman A, Mazin R, Pinzon CE, Reveiz L, Ghdinelli M. Hepatitis C in key populations in Latin America and the Caribbean: systematic review and meta-analysis. Int J Public Health 2015 Nov; 60(7):789–98. https://doi.org/10.1007/s00038-015-0708-5 PMID: 26298439

20. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006 Oct; 45(4):529–38. https://doi.org/10.1016/j.jhep.2006.05.013 PMID: 16879891

21. Chun HM, Roediger MP, Hullsie KH, Thio CL, Agan BK, Bradley WP, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2012 Jan 15; 205(2):185–93. https://doi.org/10.1093/infdis/jir720 PMID: 22147794

22. Thio CL, Smeaton L, Saulynas M, Hwang H, Saravanan S, Kulkarni S, et al. Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS 2013 Jan 14; 27(2):191–201. https://doi.org/10.1097/QAD.0b013e32835fa9884 PMID: 23032418
23. Berenguer J, Alejos B, Hernando V, Viciana P, Salavert M, Santos I, et al. Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapy. AIDS 2012 Nov 13; 26 (17):2241–6. https://doi.org/10.1097/QAD.0b013e3283574e94 PMID: 22781223

24. Tsuchiya N, Pathipanich P, Rojanawiwat A, Wichukchinda N, Koga I, Koga M, et al. Chronic hepatitis B and C virus co-infection increased all-cause mortality in HAART-naive HIV patients in northern Thailand. Epidemiol Infect 2013 Sep; 141(9):1840–8. https://doi.org/10.1017/S0950268812002397 PMID: 23114262

25. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furher J, McCabe RE, et al. Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2003 Feb 1; 36(3):363–7. https://doi.org/10.1086/345953 PMID: 12539079

26. Macera C, Ito SI, Hale BR, Shaffer RA, Thomas AG, Dickieson J. A Strategy for Conducting an HIV Seroprevalence and Behavioral Epidemiology Risk Survey (SABERS) among Partner Military Populations. Curr HIV Res 2017; 15(2):82–9. https://doi.org/10.2174/1570162X15666170516164521 PMID: 28521715

27. Ministry of Health (MOH), Bureau of Statistics (BOS) and ICF Macro. 2010. Guyana Demographic and Health Survey 2009. Georgetown, Guyana: MOH, BOS and ICF Macro. Available at: http://dhsprogram.com/pubs/pdf/FR232/FR232.pdf. Accessed 01 April 2015.

28. Ministry of Health, Guyana. National Guidelines for Management of HIV-Infected and HIV-Exposed Adults and Children. August 2006 Revision. Available at: http://www.who.int/hiv/pub/guidelines/guyana_art.pdf. Accessed 01 April 2015.

29. Ramachandran S, Zhai X, Thai H, Campos DS, Xia G, Ganova-Raeva LM, et al. Evaluation of intra-host variants of the entire hepatitis B virus genome. PLoS One 2011 Sep 20; 6(9):e25232. Accessed 27 August 2015. https://doi.org/10.1371/journal.pone.0025232 PMID: 21949887

30. Forbi JC, Vaughan G, Purdy MA, Campo DS, Xia DL, Ganova-Raeva LM, et al. Epidemic History and Evolutionary Dynamics of Hepatitis B Virus Infection in Two Remote Communities in Rural Nigeria. PLoS One 2010 Jul 19; 5(7):e11615. Accessed 27 August 2015. https://doi.org/10.1371/journal.pone.0011615 PMID: 20657838

31. Tamura K, Nei M, Kumar S. Prospects for inferring very large phylogenies by using the neighbor-joining method. 2004. Proc Natl Acad Sci U S A 2004 (Jul 27); 101(30):11030–5. https://doi.org/10.1073/pnas.0404206101 PMID: 15258291

32. Lock G, Dirisher M, Obermeier F, Gelbmann CM, Hellerbrand C, Krüll A, et al. Hepatitis C—contamination of toothbrushes: myth or reality? J Viral Hepat 2008 Sep; 15(9):571–3. https://doi.org/10.1111/j.1365-2893.2006.00735.x PMID: 16907842

33. Quereshi H, Arif A, Riaz K, Alam SE, Ahmed W, Mugeeb SA. Determination of risk factors for hepatitis B and C in male patients suffering from chronic hepatitis. BMC Res Notes 2009 Oct 23; 2:212. Accessed 15 Jun 2018 https://doi.org/10.1186/1756-0500-2-212 PMID: 19852780

34. World Health Organization. Hepatitis B vaccines. WHO position paper. Wkly Epidemiol Rec 2017 July 7; 92(27):369–92. PMID: 28685564

35. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ. HIV-HBV coinfection—a global challenge. N Engl J Med 2012 May 10; 366(19):1749–52. https://doi.org/10.1056/NEJMj1201796 PMID: 22571198

36. World Health Organization. Immunizations, vaccines and biologics. Available at: http://www.who.int/immunization/monitoring_surveillance/data/en/; Accessed 26 August 2016.

37. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection, March 2015. Available at: http://www.who.int/hiv/pub/hepatitis/hepatitis-b-guidelines/en/; Accessed 26 August 2016.

38. Republic of Guyana. 2015 Guyana AIDS Response Progress Report. Reporting Period: January-December 2014. Available from https://www.unaids.org/sites/default/files/country/documents/GUY_narrative_report_2015.pdf. Accessed 08 June 2019.